menu search

IPSC / Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.53 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.66 per share a year ago. Read More
Posted: May 11 2023, 10:40
Author Name: Zacks Investment Research
Views: 102165

IPSC News  

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 11, 2023

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.53 per share in line with the Zacks Consensus Estimate. This compares to loss o more_horizontal

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

By GlobeNewsWire
April 17, 2023

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing in more_horizontal

After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)

By Zacks Investment Research
January 17, 2023

After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)

Century Therapeutics, Inc. (IPSC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, co more_horizontal

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

By GeekWire
January 9, 2023

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Century Therapeutics is closing its Seattle operations as part of a 25% reduction in headcount and a shift in its priorities. more_horizontal

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

By Benzinga
February 8, 2022

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fa more_horizontal

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

By Benzinga
February 8, 2022

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fa more_horizontal

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

By Benzinga
February 8, 2022

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fa more_horizontal


Search within

Pages Search Results: